Chemo Regimen for Ovarian Cancer Camp Lejeune NC

Dose-dense chemotherapy improves survival in women with advanced ovarian cancer, Japanese researchers say. Currently, paclitaxel and carboplatin given every three weeks is considered standard first-line chemotherapy for advanced epithelial ovarian cancer. However, dose-dense weekly treatment with paclitaxel is seen as a way to increase progression-free and overall survival in these patients in Camp Lejeune, according to the new study findings.

Loren James Smith, MD
(910) 450-4860
100 Brewster Blvd
Camp Lejeune, NC
Specialties
Urology
Gender
Male
Education
Medical School: Med Coll Of Ga Sch Of Med, Augusta Ga 30912
Graduation Year: 1993

Data Provided by:
Ronald Mack Hammock, MD
(910) 353-9994
200 Doctors Dr Ste C
Jacksonville, NC
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Mi Med Sch, Ann Arbor Mi 48109
Graduation Year: 1977

Data Provided by:
Jay Levy, MD
(704) 540-3667
3125 Springbank Ln
Charlotte, NC
Business
Pediatric Urology Associates PA
Specialties
Urology

Data Provided by:
Kevin C Shandera, MD
(704) 541-8207
10512 Park Rd Ste 113
Charlotte, NC
Specialties
Urology
Gender
Male
Education
Medical School: Baylor Coll Of Med, Houston Tx 77030
Graduation Year: 1987

Data Provided by:
Andrew Howard Krueger
(828) 654-6015
50 Hospital Dr
Hendersonville, NC
Specialty
Urology

Data Provided by:
Booker T Keyes Jr, MD
247 Memorial Dr
Jacksonville, NC
Specialties
Urology
Gender
Male
Education
Medical School: In Univ Sch Of Med, Indianapolis In 46202
Graduation Year: 1976

Data Provided by:
Ronald Mack Hammock
(910) 353-9994
200 Doctors Dr
Jacksonville, NC
Specialty
Urology

Data Provided by:
Cary N Robertson MD
(919) 681-6788
DUMC 3833
Durham, NC
Specialties
Urology

Data Provided by:
Joel L Alvis, MD FACS
PO Box 395
Montreat, NC
Gender
Male
Education
Medical School: Tennessee
Graduation Year: 1953

Data Provided by:
Scott Cooper Stoioff
(336) 584-6300
1236 Huffman Mill Rd
Burlington, NC
Specialty
Urology

Data Provided by:
Data Provided by:

Chemo Regimen for Ovarian Cancer

Provided By:

SUNDAY, Sept. 20 (HealthDay News) -- Dose-dense chemotherapy improves survival in women with advanced ovarian cancer, Japanese researchers say.

Currently, paclitaxel and carboplatin given every three weeks is considered standard first-line chemotherapy for advanced epithelial ovarian cancer. However, dose-dense weekly treatment with paclitaxel is seen as a way to increase progression-free and overall survival in these patients, according to the new study findings.

This phase 3 study of 637 women compared the two approaches. The participants had advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

The 320 patients in the conventional regimen group received six cycles of paclitaxel (180 milligrams per meter squared; three-hour intravenous infusion). The 317 patients in the dose-dense group received paclitaxel (80 milligrams per meter squared; one-hour intravenous infusion) on days one, eight and 15. Both groups received carboplatin on day one of a 21-day cycle.

The patients in the dose-dense group had longer median progression-free survival than those in the standard treatment group (28 months versus 17 months), and longer overall survival at three years (72 percent versus 65 percent). This means that women in the dose-dense group had a 29 percent lower risk of cancer progression and a 25 percent lower risk of death, the authors explained.

Toxicity forced 113 patients in the dose-dense group and 69 patients in the conventional therapy group to stop treatment, the researchers noted. Severe anemia occurred in 214 patients (69 percent) in the dose-dense group and in 137 (44 percent) of the standard therapy group.

The survival benefits seen in the dose-dense group are rare in patients with advanced ovarian cancer, and this regimen offers a new treatment option for women with advanced epithelial ovarian cancer, concluded Dr. Noriyuki Katsumata, of the National Cancer Center Hospital in Tokyo, and colleagues.

The study, published in an upcoming print issue of The Lancet, was released online Sunday to coincide with the European Cancer Organization meeting held Sept. 20 to 24 in Berlin.

"The use of such dose-dense therapy should be decided on an individual basis together with other options for women with advanced-stage ovarian cancer," Dr. Michael A. Bookman, of the Arizona Cancer Center in Tucson, wrote in an accompanying commentary in The Lancet.

More information

The U.S. National Cancer Institute has more about ovarian cancer.

SOURCE: The Lancet, news release, Sept. 19, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com